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Abstract
SCD in pregnancy is associated with increased adverse fetal and maternal outcomes. In Tanzania where the frequency of
sickle cell trait is 13% there has been scanty data on SCD in pregnancy. With progressive improvement in childhood survival
the burden of SCD in pregnancy will increase. We analyzed all deliveries at Muhimbili National Hospital (MNH) from 1999 to
2011. Fetal and maternal outcomes of SCD deliveries were compared with non-SCD. Data were analyzed using IBM SPSS
statistics version 19. Chi square and Fisher Exact tests were used to compare proportions and the independent t-test for
continuous data. To predict risks of adverse effects, odds ratios were determined using multivariate logistic regression. A pvalue,0.05 was considered significant. In total, 157,473 deliveries occurred at MNH during the study period, of which 149
were SCD (incidence of 95 SCD per 100,000 deliveries). The incidence of SCD had increased from 76 per 100,000 deliveries in
the 1999–2002 period to over 100 per 100, 000 deliveries in recent years. The mean maternal age at delivery was lower in
SCD (24.065.5 years) than in non-SCD deliveries (26.266.0 years), p,0.001. Compared with non-SCD (2.960.7 Kg), SCD
deliveries had less mean birth-weight (2.660.6 Kg), p,0.001. SCD were more likely than non-SCD to deliver low APGAR
score at 5 minutes (34.5% Vs 15.0%, OR = 3.0, 95%CI: 2.1–4.2), stillbirths (25.7% Vs 7.5%, OR = 4.0, 95%CI: 2.8–5.8). There was
excessive risk of maternal deaths in SCD compared to non-SCD (11.4% Vs 0.4%, OR = 29, 95%CI: 17.3–48.1). The leading
cause of deaths in SCD was infections in wholly 82% in contrast to only 32% in non-SCD. In conclusion SCD in pregnancy is
an emerging problem at MNH with increased adverse fetal outcomes and excessive maternal mortality mainly due to
infections.
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be prevented by routine newborn screening and targeted standard
interventions. In countries where effective measures are undertaken to prevent morbidity and mortality due to SCD, 94–99% of the
children survive to age 18–20 years and life expectancy is on
average at least mid-50s [4–5].
Patients with SCD who survive childhood and who become
pregnant are likely to suffer aggravated morbidity and mortality.
International evidence on pregnancy outcome among SCD has
been inconsistent. Low and middle income countries generally
report increased maternal and perinatal morbidity and mortality
in association with SCD [12–15]. In Jamaica where 10% of the
population has the S gene, the risk of maternal deaths is 7–11
times higher in SCD comparing to the general population [12].
Studies in high income countries generally report more favorable
fetal outcomes without appreciable risk for increased maternal
mortality [15–17]. Although there is scanty literature on SCD in
pregnancy from Sub-Saharan Africa, the little available studies
suggest poor pregnancy outcomes in SCD with maternal mortality
varying from 1.8% to 9% [18–19]
In Tanzania pregnancy outcomes of SCD have not been
systematically documented. Generally the national maternal
mortality ratio has slightly decreased in the last decade from 578
to the current 454/100,000 live births based on the 2010
Tanzania Demographic and Health Survey (TDHS) data.
Likewise, National statistics have reported a decrease in under-

Introduction
Sickle cell disease (SCD) is a group of inherited single-gene
autosomal recessive disorders caused by the sickle cell gene which
affects hemoglobin structure [1–6]. SCD encompasses Sickle cell
Anemia (SCA) which possesses SS genotype, some heterozygous
conditions of the S gene and other clinically abnormal hemoglobins such as beta thalassemia, hemoglobin C, D, E and others.
The combination of Sickle gene with any of these abnormal
hemoglobins will lead to a similar clinical picture of SCD although
the severity of the disease and prevalence differ. SCD is believed to
originate from Sub-Saharan Africa and Middle East, hence high
prevalence is found among populations in these regions and their
descendants elsewhere in the world [7]. It is estimated 300,000
children are born each year with SCD with 75% of them living in
Sub-Saharan Africa [8–9]. SCD is a major public health problem
in East Africa. In Uganda a mean frequency of 20% Sickle cell
trait is documented, with an expected 25,000 babies born with
SCD each year [10]. Similarly high annual incidence of SCD
births can be expected in Tanzania where the quoted frequency of
Sickle cell trait is 13% [11].
SCD is associated with increased childhood morbidity and
mortality. World Health Organization estimates 50–80% SCD
patients in Sub-Saharan Africa will die before adulthood [9]. In
Tanzania the most vulnerable children to SCD mortality are those
under the age of five [11]. Most of SCD deaths in childhood could
PLOS ONE | www.plosone.org
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Table 1. Characteristics of all deliveries in MNH from 1999 to
2011.

Characteristics

Number*

Percentage

,18

7139

4.6

18–34

130833

84.9

.34

16141

10.5

Age at delivery (years)

Status of referral
Referred

28935

18.4

Not referred

128332

81.6

0–5

149069

95.9

.5

6341

4.1

,33

4247

4.0

33–36

28067

27.0

.36

71811

69.0

Negative

33401

93.9

Positive

2187

6.1

No visit

716

0.5

1–4

66140

42.5

5 or more

88550

57.0

Parity

Gestation Age(weeks)

Figure 1. Trend of annual deliveries at MNH.
doi:10.1371/journal.pone.0056541.g001

HIV status{

women (non-SCD deliveries) who delivered at MNH in the same
period. The results in this article have effectively filled the gap in
knowledge about SCD in pregnancy in Tanzania.

Antenatal visits

Methodology
Study setting
Muhimbili National Hospital (MNH) is the largest consultant
hospital in the United Republic of Tanzania being situated in Dar
es Salaam, the country’s largest city. According to the 2002
national population Census, the city has a total population of
about 3.4 million with annual growth rate of 4.3%. The maternity
unit is affiliated to the department of obstetrics and gynaecology in
the MNH structure. The unit receives referred pregnant women
from Dar es Salaam district hospitals as well as other hospitals
from within the city. Occasionally it receives patients from other
nearby regions. About 40 women deliver at this unit each day. The
MNH also serves as teaching hospital for the Muhimbili University
Health and Allied Sciences (MUHAS).

Mode of delivery
Vaginal

108068

70.4

Cesarean section

45439

29.6

,7

23102

15.0

7–10

130918

85.0

Yes

12231

7.1

No

141790

92.9

APGAR score at 5 minutes

Stilbirths

Birth weight(Kg)
,2.5

27374

17.9

2.5 or above

125848

82.1

Alive

154650

99.5

Died

706

0.45

The obstetric database
This study utilized information stored in the MNH electronic
obstetric database from 1st January, 1999 to 31st December, 2011.

Maternal outcome

*Missing data are not included. In all variables, missing data accounted for less
than 5%.
{
In only 35,588 (22.6%) of all deliveries was HIV status known.
doi:10.1371/journal.pone.0056541.t001

five mortality from 106 deaths per 1000 live births 5–9 years ago
down to the current 81 deaths per 1000 live births [20]. Since most
of SCD deaths in Tanzania occur among children under the age of
five years [11], improved general childhood survival can result in
increased SCD population of women in the reproductive age and
a rise in SCD deliveries. This study was conducted in order to
provide baseline data on the trend of SCD deliveries over the past
13 years (1999–2011) and adverse maternal and fetal outcomes
among SCD deliveries in Tanzania. The objective was to compare
outcomes of SCD deliveries with that of the general population of

PLOS ONE | www.plosone.org

Figure 2. Trend of SCD deliveries at MNH.
doi:10.1371/journal.pone.0056541.g002
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Table 2. Comparison of prenatal characteristics and pregnancy outcomes among SCD and non SCD deliveries at MNH, 1999–2011.

Characteristics

SCD*

Non-SCD*

p-Value

OR

95%CI

Mean Age at delivery (±SD yrs)

24.0 (65.5)

26.2(66.0)

,0.001

1.7

1.2–2.5

0.2

0.08–0.7

1.3

0.9–1.9

0.5

0.9

0.6–1.2

Status of referral
Referred

107 (72.3)

126972 (81.9)

Not referred

41 (27.7)

28115 (19.1)

0.003

Mean Parity

1.7(61.0)

2.2(61.5)

,0.001

0–5

148(99.3)

148921(95.9)

.5

1 (0.7)

6340 (4.1)

0.01

Mean Gestation Age(weeks)

37.0(62.3)

37.3(62.1)

0.1

Yes (,37)

41(36.9)

32273(31.0)

0.18

No (37 or more)

70(63.1)

71741(69.0)

Mean Antenatal visits

5.3 (62.4)

5.3(62.6)

Parity

Premature delivery

0.8

Mode of delivery
Vaginal

109(73.2)

107959(70.4)

Cesarean section

40(26.8)

45399(29.6)

,7

51(34.5)

23051(15.0)

7–10

97(65.5)

130821(85.0)

,0.001

3.0

2.1–4.2

,0.001

4.0

2.8–5.8

APGAR score at 5 minutes

Stilbirths
Yes

38(25.7)

12193(7.9)

No

110(74.3)

141680(92.1)

Mean birth weight(Kg±SD)

2.6(60.6)

2.9(60.7)

,0.001

Yes (,2.5)

50 (34.2)

27324 (17.8)

,0.001

2.4

1.7–3.4

No (2.5 or above)

96(65.8)

125752(82.2)

,0.001

28.9

17.3–48.1

Low birth weight(Kg)

Maternal outcome
Alive

132(88.6)

154518(99.6)

Died

17(11.4)

689(0.4)

*Unless specified otherwise data are displayed as number (%).
doi:10.1371/journal.pone.0056541.t002

The database was established in 1998 and since then data have
been prospectively entered. Patients admitted to the MNH labor
ward bring their antenatal (RCH4) cards and the information is
entered into the admission book on arrival. Chronic maternal
diseases such as SCD are indicated in this card. After delivery,
antenatal information such as antenatal diagnoses and risk factors
from the RCH4 card are computerized together with data on
labor, maternal and neonatal outcomes from the midwifery book.
The obstetric database thus contains information on: maternal
age, marital status, parity, antenatal diagnoses, APGAR scores at
one and five minutes, birth weight, maternal and fetal outcomes as
well as maternal complications. MNH has a maternal death audit
committee which discusses all maternal deaths regarding the
causes and the information is entered in the database. Validity of
data is ensured by a data quality program run weekly and the
validity checks of the data done twice annually. The latter is done
by annual comparison, between the information in the ledgers
with the information, in the database for selected variables. From
the electronic obstetric database we identified all deliveries during
the entire study period and analyzed their data.

PLOS ONE | www.plosone.org

Data processing and analysis
All the needed variables were scrutinized for missing or
inappropriately entered data. It was agreed at the start of analysis
that any variable with 5% or more missing data will be excluded.
A comparison was made between SCD deliveries and the general
population of deliveries without a diagnosis of SCD. In multiple
pregnancies, only data for the first born were considered.
Comparison of means for continuous variables was done using
the independent t-test. Proportions were compared using Chi
square or Fisher exact test as appropriate. In all the comparisons,
p-value less than 0.05 were considered significant.

Ethics statement
This study was ethically approved by the MUHAS ethical and
publication committee and the permission to use the database was
obtained from MNH Authorities.

Results
During the study period there were 157,473 deliveries at MNH
of which 151,518 were singleton. There were 149 SCD deliveries
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Of the 149 SCD deliveries, deaths occurred in 17 which make
the incidence of maternal death of 1141 per 100,000 deliveries
compared to 439 per 100,000 deliveries for non SCD deliveries.
Thus the risk of dying was 29 times for SCD as for the non-SCD
deliveries (Table 2).
Figure 3A and 3B display the causes of maternal deaths for SCD
and non-SCD deliveries. The most frequent causes of deaths
among non-SCD were eclampsia/PIH (24%), hemorrhage (22%)
and anemia (16%). In contrast, the causes of deaths in 82% of
SCD deliveries were infections. These infections include malaria
(58.8%), sepsis (11.8%) and HIV/AIDS (11.8%). Hemorrhage was
not a major cause of deaths in SCD.

Discussion
Sickle cell anemia is a major public health problem in Tanzania
[11] but more attention has been drawn to SCD in childhood with
almost none paid to SCD in pregnancy. As childhood survival
continue to improve [20], the burden of SCD in pregnancy will
continue to rise as proved by this study. The SCD incidence of 95
per 100, 000 deliveries and a rising trend of SCD deliveries from
76 per 100,000 deliveries in 1999–2002 to over 100 per 100, 0000
deliveries in more recent years, underscores the need for paying
more attention to SCD in pregnancy.
The objective of the current study was to compare outcomes of
SCD deliveries with those of the general population of women
who delivered at MNH without the diagnosis of SCD. We found
that SCD deliveries were significantly younger and of lower parity
than in non-SCD which is supported by some studies [12] but not
all. In the contrary, Serjeant and others have reported older age at
delivery in SCD than in non-SCD [21]. It remains unclear if the
differences in age at delivery and parity could be attributable by
differences in knowledge and practice of timing of pregnancy
among SCD women. Although studies show delayed menarche
among SCD, they do not generally support early timing of first
pregnancy for SCD women [21–23]. Timing of conception and
spacing of pregnancy is particularly important among SCD and
future studies should seek to address this gap in knowledge.
All SCD mothers in the current study sought antenatal care and
nearly a third came directly from home to seek delivery at a
tertiary hospital. Despite their efforts to seek the best health care
services, maternal and perinatal outcomes were generally poor.
Compared with non-SCD, SCD deliveries had lower birth
weights, poorer APGAR scores at one and five minutes, and
increased stillbirth rate. These findings support findings by studies
from low income and higher income countries [13,15–16,18–
19,21,24] indicating common difficulties experienced in improving
fetal outcomes even with the standard management measures in
place. Unlike some other studies that show increased prematurity
rate among SCD [15–16,21,25], the current study did not find a
statistically significant difference in prematurity rate and gestation
age at delivery among SCD and non-SCD. This discrepancy could
be explained by the failure of this study to take into account of
women who did not deliver at MNH, and the presence of multiple
factors contributing to prematurity in the study population. A third
of all deliveries (31%) took place at the gestation age of less than 37
weeks. Future prospective studies should help to clarify this for
Tanzania.
Maternal mortality was very alarming with an incidence of 1149
deaths per 100,000 SCD deliveries compared with 439 per
100,000 deliveries for non SCD in this study and the 1.8% to 9%
in West Africa [18–19]. In the current study, the risk of death was
29 times higher for SCD as for non-SCD which is much higher
than the 7–11 in Jamaica [12]. Nevertheless, this extremely high

Figure 3. Causes of maternal deaths in non-SCD population(A).
(B)Causes of maternal deaths in SCD.
doi:10.1371/journal.pone.0056541.g003

which makes the incidence of 95 SCD per 100,000 deliveries.
Overall, the median age at delivery was 26(66.0) years with a
range of 12–50 years. From Table 1, most deliveries (84.9%) were
to mothers in the relatively low risk age range of 18–34 years.
Attendance to antenatal clinic was 99.5% of all deliveries. Around
18% of all the deliveries had low birth weight, and 7.1% were
stillbirths. Overall there were 706 maternal deaths which is
equivalent to 448 deaths per 100,000 deliveries at this hospital.
During the study period deliveries at MNH had gone down by
over 50%. Figure 1 indicates a steady decline in all annual
deliveries from 18,158 in 1999 to 8000 in 2008. Since 2009 there
has been a gradual increase to 10441 deliveries in 2011.
The incidence of SCD deliveries had increased from 76 per
100,000 deliveries in the first four years (1999–2002) to over 100
per 100,000 deliveries in subsequent similar periods (Figure 2).
A comparison of characteristics of SCD deliveries and the
general population (non-SCD deliveries) is demonstrated in
Table 2. SCD deliveries were significantly younger and of lower
parity than non-SCD deliveries. The mean number of antenatal
visits, the gestation age at delivery and mode of delivery were not
statistically different among the two groups.
Comparing with non-SCD deliveries, SCD had a 2.4 risk of
delivering low birth weight babies. The risk of low APGAR score
at five minutes was 3 times for SCD as for the non-SCD
population. A total of 12588 (8.0%) of all the deliveries never
survived the first five minutes of birth including 38 (25.7%) of SCD
and 12193(7.9%) of the general population, (p,0.001). The risk of
a newborn scoring 0 after 1 minute or after 5 minutes was 4 times
in SCD as for non-SCD deliveries.

PLOS ONE | www.plosone.org
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maternal mortality was comparable with that reported in Nigeria
[26]. Excessive maternal deaths can be prevented by improved
care as has been the case in developed countries with standard
care of SCD in pregnancy where maternal deaths due to SCD is
uncommon [16]. With improved prenatal care good outcomes
have also been reported in some African settings [18].
In the current study, the most frequent causes of deaths among
non-SCD were eclampsia/PIH (24%), hemorrhage (22%) and
anemia (16%). In contrast, the causes of deaths in 82% of SCD
deliveries were infections with two thirds of them being due to
malaria alone. The pathophysiological mechanisms of deaths due
to malaria infection in SCD pregnancies are not fully understood.
In childhood SCD does not seem to increase the risk of malaria
infection although SCD increases the risk of severe morbidity and
dying among hospitalized patients [27–28]. Whether this is the
case for SCD in pregnancy, it remains to be established. What is
clear from this study is that interventions to prevent malaria
parasitemia in pregnancy, adherence to aseptic techniques during
labor and delivery in order to minimize sepsis and HIV screening
and treatment should constitute the minimum requirements for
care of SCD. Health professionals should be prepared to
effectively diagnose and manage SCD in pregnancy. It is also
necessary for women with SCD, their partners and families to
receive extensive education and counseling on the complications of
SCD in pregnancy if these complications are to be minimized.
These findings call for urgent need to introduce standard care for
SCD women who contemplate pregnancy or become pregnant in
Tanzania.
Our study utilized database information which, similar to other
retrospective sources, suffered data incompleteness. Incompleteness of some useful socio-demographic variables and intrapartum
variables such as induction of labor, premature rupture of

membranes and others limited our analysis. Moreover, the
diagnosis of SCD was made before admission in all of them and
data concerning specific genotypic disorders were lacking. In order
to protect validity of the analyzed variables we decided a priori to
include variables with not more than 5% missed values and whose
distribution of missing values was similar for SCD and non-SCD.
This was a hospital based study for women who came for delivery
at MNH. It does not contain information on early pregnancy
losses. In Dar es Salaam only about a quarter of childhood SCD
die in hospital [11], but for SCD in pregnancy this is likely to be
different. Statistics for pregnant women in Dar es Salaam [20]
indicate a high antenatal care attendance (100%) and hospital
delivery (90%) among pregnant women. This implies that our
study population may not differ markedly from the community
population of delivering women. Strength of this study is that it is
one of the largest studies done on SCD in pregnancy in SubSaharan Africa and the only one in Tanzania. The findings in this
study can be reliably used as baseline for policy change.

Conclusion
The incidence of SCD delivery at MNH has been on a rise in
the past 13 years. The disease is associated with excessive maternal
deaths that are by far attributable to infections. Standard
guidelines to improve care of SCD in pregnancy are urgently
needed in Tanzania.
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